KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2016 - 2025)

Rigel Pharmaceuticals has reported Cash & Equivalents over the past 16 years, most recently at $40.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 28.49% year-over-year to $40.6 million; the TTM value through Dec 2025 reached $40.6 million, down 28.49%, while the annual FY2025 figure was $40.6 million, 28.49% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $40.6 million at Rigel Pharmaceuticals, down from $48.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $84.8 million in Q2 2021 and troughed at $18.9 million in Q4 2021.
  • A 5-year average of $39.3 million and a median of $38.2 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 132.59% in 2021 and later crashed 67.93% in 2022.
  • Year by year, Cash & Equivalents stood at $18.9 million in 2021, then increased by 29.48% to $24.5 million in 2022, then skyrocketed by 34.04% to $32.8 million in 2023, then skyrocketed by 73.08% to $56.7 million in 2024, then dropped by 28.49% to $40.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for RIGL at $40.6 million in Q4 2025, $48.5 million in Q3 2025, and $53.4 million in Q2 2025.